Savvy Trades and Investments

[researcher59]

HALO (36.00) had only $18M interest expense for 2023 compared to $387M operating income. So very trivial interest on convertible bonds which don't mature until 2027 and 2028. Presumably they'll roll them over before they come due. There is no problem with their debt load especially the way the business is growing. Also drug companies are generally not very impacted by economic downturns.

I plan to add shares to my position tomorrow. The stock looks very undervalued if their growth projections are anywhere near accurate.